An 8K came out this morning...along with a bunch of other junk, I don't beleive to be BMSN related...I couldn't find the relationship to BMSN...If anyone else figures it out, please let me know what it is! Thanks.
http://ih.advfn.com/p.php?pid=nmona&article=59431451
Current Report Filing (8-k)
10/01/2013 @ 6:02AM
Bio-matrix Scientific Group, Inc. (QB) (BMSN)
Item 1.01 Entry into a Material Definitive Agreement.
On September 23, 2013 Regen BioPharma, Inc. (“Regen”), a subsidiary of Bio-Matrix Scientific Group, Inc. (the “Company”) executed an agreement entered into by and between Wei Ping Min, PhD. (“Min”) and Regen dated July 27, 2013 (“Agreement”) intended to memorialize the contractual relationship between the parties.
Pursuant to the terms of the Agreement, Min shall be required to conduct for Regen preclinical testing with regards to products under development by Regen as well as provide regulatory assistance to Regen in connection with Regen’s Investigational New Drug (IND) Application for HemaXellerate which was filed February 4, 2013 with the United States Food and Drug Administration.
The duration of the Agreement shall be from July 27, 2013 to June 30, 2014. Pursuant to the Agreement, Min shall be entitled to receive compensation in the amount of $100,000. This payment shall be made in installments and shall be made in the common stock of the Regen’s parent company, Bio-Matrix Scientific Group Inc. The shares of common stock issued to Min pursuant to the Agreement may be registered under the Securities Act of 1933 or may be paid as “restricted securities”, as that term is defined in Rule 144 promulgated under the Securities Act of 1933, at the discretion of the Company. Shares of the Company’s common stock issued as payment to Min shall be valued at the closing price on the trading day immediately prior to issuance.